<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A site in the Epstein-Barr virus (EBV) transforming protein LMP1 that constitutively associates with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor 1 (TNFR1)-associated <z:hpo ids='HP_0011420'>death</z:hpo> domain protein TRADD to mediate NF-kappaB and c-Jun N-terminal kinase activation is critical for long-term lymphoblastoid cell proliferation </plain></SENT>
<SENT sid="1" pm="."><plain>We now find that LMP1 signaling through TRADD differs from TNFR1 signaling through TRADD </plain></SENT>
<SENT sid="2" pm="."><plain>LMP1 needs only 11 amino acids to activate NF-kappaB or synergize with TRADD in NF-kappaB activation, while TNFR1 requires approximately 70 residues </plain></SENT>
<SENT sid="3" pm="."><plain>Further, LMP1 does not require TRADD residues 294 to 312 for NF-kappaB activation, while TNFR1 requires TRADD residues 296 to 302 </plain></SENT>
<SENT sid="4" pm="."><plain>LMP1 is partially blocked for NF-kappaB activation by a TRADD mutant consisting of residues 122 to 293 </plain></SENT>
<SENT sid="5" pm="."><plain>Unlike TNFR1, LMP1 can interact directly with receptor-interacting protein (RIP) and stably associates with RIP in EBV-transformed lymphoblastoid cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>Surprisingly, LMP1 does not require RIP for NF-kappaB activation </plain></SENT>
<SENT sid="7" pm="."><plain>Despite constitutive association with TRADD or RIP, LMP1 does not induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in EBV-negative Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or human embryonic kidney 293 cells </plain></SENT>
<SENT sid="8" pm="."><plain>These results add a different perspective to the molecular interactions through which LMP1, TRADD, and RIP participate in B-lymphocyte activation and growth </plain></SENT>
</text></document>